E-ISSN 2577-5669
 

Research Article 


Formulation Development and evaluation of Liposomal Drug Delivery System Containing Etoposide

FUGATE AJAY R, NAGOBA SHIVAPPA N, S. R. HYAM.

Cited by (2)

Abstract
Two most commonly used preparative methods, reverse phase evaporation and ethanol injection were employed to prepare cationic liposomes composed of Etoposide API, DMPG-Na polymer and Cholesterol binder, respectively. To overcome the hindrances of the reported HPLC analytical method in pharmacopeia which requires more time in preparation for solvent and also its bit tedious; we have developed and validated a simple method which will be applicable to detect and quantify actual drug in formulation as well as it can be applied for pharmacokinetics study. The resulting formulations were evaluated through morphology observation, particle size and zeta potential analysis, % entrapment efficiency and % drug loading. The results showed that liposomes prepared by ethanol injection method were of best quality and stability, with promising results. However ETNLE 5 shows best results i.e. particle size 197.3±0.21nm, polydispersity index 0.340±0.051%, and zeta potential of about -12.7±1.266mV. Entrapment efficiency 81.78± 0.78% and drug loading 89.62±2.53% is the highest as compared to all other batches. % In-vitro Drug release study showed 15% and 21% of drug was released in the first five minutes with a cumulative drug release of 58% and 78% for ETNLE 5 formulation at pH 1.2 and pH 6.4 respectively. Stability study of optimized batch showed no significant changes in evaluation parameters. Cell viability study on A-549 cells by MTT assay clarified cancer cells are inhibited by 200 μM equivalent etoposide liposomes as compared to 64.88% of free drug. These findings clarified the effect of preparative methods on performance of cationic liposome, as well as formulation factors on entrapment efficiency, and will provide important methodological reference for further study of liposomes carriers for drug delivery to tumor penetration.

Key words: Etoposide; Liposome; Entrapment efficiency; Ethanol injection; Reverse phase evaporation.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by FUGATE AJAY R
Articles by NAGOBA SHIVAPPA N
Articles by S. R. HYAM
on Google
on Google Scholar


REFERENCES
1. Dogan O. Dirençli obsesif kompulsif bozukluk ve tedavi seçenekleri. Anadolu Psikiyatri Derg 2010; 11:269-278.
2. Bulut M, Virit O, Çopoglu ÜS, Bulbul F, SavaĢ HA. Gebelikte duygudurum bozukluklarinin tedavisinde EKT kullanimi. Anadolu Psikiyatri Derg 2009; 10(Ek 1):76-77.
3. Tomruk NB, Oral T. Elektrokonvulsif tedavinin klinik kullanimi: Bir gozden geçirme. Anadolu Psikiyatri Derg 2007; 8:302-309.
4. Gaines GY, Rees DI. Anesthetic considerations for electroconvulsive therapy. South Med J 1992; 85:469-482. [DOI via Crossref]    [Pubmed]   
5. Zeren T, Tamam L, Evlice YE. Elektrokonvulsif terapi: 12 yillik uygulamanin degerlendirilmesi. Yeni Symposium 2003; 41:54-63.
6. Yildiz A, Gokmen N, Turgut K, Yucel G, Tunca Z. Bir universite hastanesi yatakli psikiyatri servisinde uygulanan somatik tedaviler arasinda elektrokonvulsif tedavinin yeri. Klinik Psikofarmakoloji Bulteni 2003; 13:65-71.
7. Saatcioglu Ö, Tomruk NB. Practice of electroconvulsive therapy at the research and training hospital in Turkey. Soc Psychiatry Psychiatr Epidemiol 2008; 43:673-677. [DOI via Crossref]    [Pubmed]   
8. Andreasen NC. Scale for the Assesment of Positive Symptoms. Department of Psychiatry College of Mepclicine the University of lowa, 1984.
9. Erkoç ġ, Arkonaç O, Atakli C, Özmen E. Negatif semptomlari degerlendirme olçeginin guvenilirligi ve geçerliligi. DuĢunen Adam 1991; 4:14-15.
10. Andreasen NC. Scale for the Assesment of Positive Symptoms, Department of Psychiatry College of Medicine the University of lowa, 1984.
11. Erkoç ġ, Arkonaç O, Atakli C, Özmen E. Pozitif semptomlari degerlendirme olçeginin guvenilirligi ve geçerliligi. DuĢunen Adam 1991; 4:20-24.
12. Overall JE, Gorham DR. The Brief Psychiatric Rating-Scale. Psychol Rep 1962; 10:799-812. [DOI via Crossref]   
13. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
14. Akdemir A, Örsel SD, Dag Ġ,Turkçapar H, ĠĢcan N, Özbay H. Hamilton depresyon derecelendirme olçeginin geçerliligi-guvenilirligi ve klinikte kullani-mi. 3P Dergisi 1996; 4:251-259.
15. Young RC, Bigss T, Ziegler. A rating scale for mania: Reliability, validity, and sensitivity. Br J Psychiatry 1978; 133:429-435. [DOI via Crossref]    [Pubmed]   
16. Karadag F, Oral ET, Yalçin FA, Erten E. Young Mani Derecelendirme Ölçeginin Turkiye‟de geçerlik ve guvenilirligi. Turk Psikiyatri Dergisi 2001; 13:107-114.
17. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised US Dept Health, Education and Welfare Publication (ADM), Rockville, MD; National Institute of Mental Health, 1976, p.76-338.
18. EĢsizoglu A, YaĢan A, Bulbul Ġ, Akkoç H, Yildirim EA, Özkan M. Depresyon hastalarinda, nobet geçirme suresi ve uygulanan elektriksel dozun, elektrokonvulsif tedaviye verilecek klinik yanit hizi ile iliĢkisi: Retrospektif bir çaliĢma. Anadolu Psikiyatri Derg 2009; 10:286-292.
19. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33:766-771. [DOI via Crossref]    [Pubmed]   
20. Shukla GD. Electroconvulsive therapy: a review. Indian J Psychiatry 1989; 31:97-115.
21. Odejide AO, Ohaeri JU, Ikuesan BA. Electroconvulsive therapy in Nigeria. Convuls Ther 1987; 3:31-39.
22. Minhas HM, Ostroff R. Practice of electroconvulsive therapy in a tertiary care hospital in Pakistan. J ECT 2011; 28:7-9.
23. Daradkeh TK, Saad A, Younis Y. Contemporary status of electroconvulsive therapy in a teaching psychiatric unit in Al Ain, United Arab Emirates. Nord J PsychiatrY 1998; 52:481-485. [DOI via Crossref]   
24. Tauscher J, Neumeister A, Fischer P, Frey R, Kasper S. Electroconvulsive therapy in clinical practice. Nervenartz 1997; 65:410-416. [DOI via Crossref]   
25. Andersson JE, Bolwig TG. Electroconvulsive therapy in Denmark in 1999: a nation-wide questionnaire study. Ugeskr Laeger 2002; 164:3449-3452.
26. Von Schweder LJ, Lydersen S, Wahlund B, Bergsholm P, Linaker OM. Electroconvulsive Therapy in Norway: Rates of Use, Clinical Characteristics, Diagnoses, and Attitude. J ECT 2011; 27:292-295. [DOI via Crossref]    [Pubmed]   
27. Gazdag G, Palinska D, Kloszewska I, Sobow T. Electroconvulsive therapy practice in Poland. J ECT 2009; 25:34-38. [DOI via Crossref]    [Pubmed]   
28. Fink M. Convulsive therapy: A review a of first 55 years. J Affect Disord 2001; 63:1-5. [DOI via Crossref]   
29. Sylvester AP, Mulsant BH, Chengappa KNR, Sandman AR, Haskett RF. Use of electroconvulsive therapy in a State Hospital: A 10-years review. J Clin Psychiatry 2000; 61:534-539. [DOI via Crossref]    [Pubmed]   
30. American Psychiatric Association (APA) Task Force on ECT. The practice of ECT: recommendations for treatment, training and privileging. Washington DC, APA Press, 1990.
31. Freeman CP. The Second Report of the Royal College of Psychiatrists‟ Special Committee on ECT. The ECT Handbook. London, Royal College of Psychiatrists, 1995.
32. Virit O, Altindag A, Akçali A, Bulut M, SavaĢ HA. Parkinson hastaligi, psikoz ve depresyonu olan uç olgunun elektrokonvulsif tedavi ile etkili tedavisi. Anadolu Psikiyatri Derg 2010; 11:79-82.
33. Kaplan HI, Sadock BJ, Grebb JA. Synopsis of Psychiatry. Seventh ed., Baltimore: Williams & Wilkins, 1994, p.1005-1011.
34. Weiner RD. Convulsive therapy: 50 years later. Am J Psychiatry 1984; 141:1078-1079.
35. Chanpattana W, Kunigiri G, Kramer BA, Gangadhar BN. Survey of ECT practice in teaching hospitals in India. J ECT 2005; 21:100-104. [DOI via Crossref]    [Pubmed]   
36. Chanpattana W, Kojima K, Kramer BA, Intakorn A, Sasaki S, Kitphati R. ECT practice in Japan. J ECT 2005; 21:139-144. [DOI via Crossref]    [Pubmed]   
37. Chanpattana W, Kramer BA. Electroconvulsive therapy practice in Thailand. J ECT 2004; 20:94 -98. [DOI via Crossref]    [Pubmed]   
38. Chanpattana W, Kramer BA, Kunigiri G, Gangadhar BN, Kitphati R, Andrade C. ECT practice in Asia. J ECT 2007; 23:53. (Meeting Abstracts: 2007 ACT/ISTS Scientific Program)
39. Ishimoto Y, Imakura A, Nakayama H. Practice of electroconvulsive therapy at university hospital, the university of Tokushima school of medicine from 1975 to 1997. J Med Invest 2000; 47:123 -127.
40. Teh SP, Xiao AJG, Helmes E, Drake DG. Electroconvulsive therapy practice in Western Australia. J ECT 2005; 21:145-150. [DOI via Crossref]    [Pubmed]   
41. Evlice YE. Elektrokonvulsif terapi. C Guleç, E Koroglu, (Eds.), Psikiyatri Temel Kitabi, 2. cilt, Ankara, MedicoGraphics, 1998, s.1019-1034.
42. Stevens A, Fischer A, Bartels M, Buchkremer G. Electroconvulsive therapy: A review on indications, methods, risks and medication. Eur Psychiatry 1996; 11:165-174. [DOI via Crossref]   
43. Coffey CE, Weiner RD. Electroconvulsive therapy: An update. Hosp Community Psychiatry 1990; 41:515.
44. Eranti SV, Thirthalli J, Pattan V, Mogg A, Pluck G, Velayudhan L, et al. Comparison of electroconvulsive therapy practice between London and Bengaluru. J ECT 2011; 27:275-280. [DOI via Crossref]    [Pubmed]   
45. Atagun MI, Yildirim MS, Canbek Ö. Electroconvulsive therapy: an update. Current Approaches in Psychiatry 2012; 4:350-370.
46. Milstein V, Small IF. An after discharge window for ECT? Biol Psychiatry 1984; 19:1143-1148.
47. Kho KH, Blansjaar BA, Vothknecht S, Cornelissen NMP, Koomen E, Zwinderman AH, et al. A study into predictors for the speed of response to electroconvulsive therapy. J ECT 2004; 20:154-159. [DOI via Crossref]    [Pubmed]   
48. Sackeim HA, Prudic J, Devanand DP, Kiersky JE, Fitzsimons L, Moody BJ, et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive side effects of electroconvulsive therapy. N Eng J Med 1993; 328:839-846. [DOI via Crossref]    [Pubmed]   
49. Nobler MS, Sackeim HA, Slomou M, Luber B, Devanand DP, Prudic J. EEG manifestations during ECT: effects of electrode placement and stimulus intensity. Biol Psychiatry 1993; 34:321-330. [DOI via Crossref]   
50. Gangadhar BN, Subbakrishna DK, Janakiramaiah N, Motreja S, Narayana Dutt D, Paramehwara G. Post-seizure EEG fractal dimension of first ECT predicts antidepresants response at two weeks. J Affect Disord 1999; 52:235-238. [DOI via Crossref]   
51. Tomruk NB, Kutlar MT, MengeĢ OO, Canbek O, Soysal H. Elektrokonvulsif Tedavi Klinik Uygulama El Kitabi. Ġstanbul, Saglik Bakanligi, 2007.
52. Rice EH, Sombrotto LB, Markowitz JC, Leon AC. Cardiovascular morbidity in high-risk patients during ECT. Am J Psychiatry 1994; 151:1637-1641.
53. Ceylan ME, Oral ET. AraĢtirma ve Klinik Uygulamada Biyolojik Psikiyatri: Duygudurum Bozukluklari. Dorduncu cilt, Ġstanbul: Nobel Yayinevi 2001, s.401-419.

This Article Cited By the following articles

Practice of Acute and Maintenance Electroconvulsive Therapy in the Psychiatric Clinic of a University Hospital from Turkey: between 2007 and 2013
Clin Psychopharmacol Neurosci 2016; 14(1): 57.

1
 
Comparison of Clinical Characteristics of Patients on whom Electroconvulsive Therapy was Applied as Inpatient and Outpatient
Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 2016; 26(1): 32.

2
 
How to Cite this Article
Pubmed Style

FUGATE AJAY R, NAGOBA SHIVAPPA N, S. R. HYAM. Formulation Development and evaluation of Liposomal Drug Delivery System Containing Etoposide. J Complement Med Res. 2021; 12(4): 7-20. doi:10.5455/jcmr.2021.12.04.02


Web Style

FUGATE AJAY R, NAGOBA SHIVAPPA N, S. R. HYAM. Formulation Development and evaluation of Liposomal Drug Delivery System Containing Etoposide. https://www.jocmr.com/?mno=35953 [Access: November 03, 2022]. doi:10.5455/jcmr.2021.12.04.02


AMA (American Medical Association) Style

FUGATE AJAY R, NAGOBA SHIVAPPA N, S. R. HYAM. Formulation Development and evaluation of Liposomal Drug Delivery System Containing Etoposide. J Complement Med Res. 2021; 12(4): 7-20. doi:10.5455/jcmr.2021.12.04.02



Vancouver/ICMJE Style

FUGATE AJAY R, NAGOBA SHIVAPPA N, S. R. HYAM. Formulation Development and evaluation of Liposomal Drug Delivery System Containing Etoposide. J Complement Med Res. (2021), [cited November 03, 2022]; 12(4): 7-20. doi:10.5455/jcmr.2021.12.04.02



Harvard Style

FUGATE AJAY R, NAGOBA SHIVAPPA N, S. R. HYAM (2021) Formulation Development and evaluation of Liposomal Drug Delivery System Containing Etoposide. J Complement Med Res, 12 (4), 7-20. doi:10.5455/jcmr.2021.12.04.02



Turabian Style

FUGATE AJAY R, NAGOBA SHIVAPPA N, S. R. HYAM. 2021. Formulation Development and evaluation of Liposomal Drug Delivery System Containing Etoposide. Journal of Complementary Medicine Research, 12 (4), 7-20. doi:10.5455/jcmr.2021.12.04.02



Chicago Style

FUGATE AJAY R, NAGOBA SHIVAPPA N, S. R. HYAM. "Formulation Development and evaluation of Liposomal Drug Delivery System Containing Etoposide." Journal of Complementary Medicine Research 12 (2021), 7-20. doi:10.5455/jcmr.2021.12.04.02



MLA (The Modern Language Association) Style

FUGATE AJAY R, NAGOBA SHIVAPPA N, S. R. HYAM. "Formulation Development and evaluation of Liposomal Drug Delivery System Containing Etoposide." Journal of Complementary Medicine Research 12.4 (2021), 7-20. Print. doi:10.5455/jcmr.2021.12.04.02



APA (American Psychological Association) Style

FUGATE AJAY R, NAGOBA SHIVAPPA N, S. R. HYAM (2021) Formulation Development and evaluation of Liposomal Drug Delivery System Containing Etoposide. Journal of Complementary Medicine Research, 12 (4), 7-20. doi:10.5455/jcmr.2021.12.04.02